Document Detail

Treatment with recombinant human erythropoietin in children with malignancies.
MedLine Citation:
PMID:  8721025     Owner:  NLM     Status:  MEDLINE    
The effect of recombinant human erythropoietin (rHuEPO) on the anemia of cancer was examined in 15 children with hematologic malignancies (group I) and solid tumors (group II), whose hemoglobin (Hb) was under the third percentile for sex and age. The response to rHuEPO was defined as an increase of Hb to above the 10th percentile following 8 weeks of therapy. The rHuEPO caused an increase in the Hb and hematocrit (Hct) in 46% of children of both groups at a dose of 150 IU/L, in 28.5% of children at a dose of 250 IU/L and in 25.5% of children at a dose of 400 IU/L. Leukocyte and platelet counts were not influenced by the rHuEPO treatment. The red cell transfusion requirement decreased to 66% in both groups after rHuEPO treatment. Erythropoietin (EPO) levels were measured prior to the treatment and then every 4 weeks during rHuEPO treatment. Children who responded to EPO had an initial EPO level of < 100 IU/L, while those who did not respond had an initial EPO level of > 100 IU/L. Erythropoietin was well tolerated in all children, with no side effects.
I Bolonaki; E Stiakaki; E Lydaki; H Dimitriou; A Kambourakis; T Kalmantis; M Kalmanti
Related Documents :
2056975 - The conduct of phase i-ii clinical trials in children with cancer.
2257545 - Has modern management improved the outcome of infants with intracranial tumors?
7761155 - Postoperative small-bowel intussusception in children with cancer.
16317745 - Should children at risk for familial adenomatous polyposis be screened for hepatoblasto...
8803395 - Gallium alloy restorations in primary teeth: a 12-month study.
21736605 - Quality of life and clinical features in swedish children with psoriasis.
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Pediatric hematology and oncology     Volume:  13     ISSN:  0888-0018     ISO Abbreviation:  Pediatr Hematol Oncol     Publication Date:    1996 Mar-Apr
Date Detail:
Created Date:  1996-09-26     Completed Date:  1996-09-26     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8700164     Medline TA:  Pediatr Hematol Oncol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  111-21     Citation Subset:  IM    
Department of Pediatric Hematology-Oncology, University of Crete, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia / blood,  complications*
Blood Transfusion
Child, Preschool
Erythropoietin / adverse effects,  blood,  therapeutic use*
Ferritins / blood
Hematologic Diseases / blood,  drug therapy*
Hemoglobins / metabolism
Neoplasms / blood,  complications*
Recombinant Proteins / adverse effects,  blood,  therapeutic use
Reg. No./Substance:
0/Hemoglobins; 0/Recombinant Proteins; 11096-26-7/Erythropoietin; 9007-73-2/Ferritins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Extramedullary nasal plasmacytoma--an unusual clinical entity.
Next Document:  Burkitt's lymphoma in 63 Turkish children diagnosed over a 10 year period.